Setting

Asia Pacific Ophthalmic Drug Delivery System Market 2021-2031 by Product (Syringes, Eyedroppers, Dispensers, Sprayers, Contact Lenses, Inserts, Implants, Plugs), Dosage Form (Solutions, Gels, Ointments, Suspensions, Emulsions, Liposomes & Nanoparticles), Disease (Glaucoma, Diabetic Retinopathy, Cataract, Dry Eye Syndrome, Macular Degeneration, Diabetic Macular Edema, Refractive Issues), Setting (Hospitals, Clinics, Homecare Settings, ASCs, Others), and Country: Trend Forecast and Growth Opportunity

Published: 30 Jun 2022 | Report Code: 10248553 | Pages: 124

Asia Pacific ophthalmic drug delivery system market will grow by 8.9% annually with a total addressable market cap of $56,139.1 million over 2022-2031, driven by the growing prevalence of ophthalmic diseases, the emerging novel ocular drug delivery systems, rise in number of ophthalmic procedures that require attentive post procedural care, and the increasing demand to deliver controlled dosage forms for pediatric and geriatric population. Highlighted with 27 tables and 56 figures, this 127-page report “Asia Pacific Ophthalmic Drug Delivery System Market 2021-2031 by Product (Syringes, Eyedroppers, Dispensers, Sprayers, Contact Lenses, Inserts, Implants, Plugs), Dosage Form (Solutions, Gels, Ointments, Suspensions, Emulsions, Liposomes & Nanoparticles), Disease (Glaucoma, Diabetic Retinopathy, Cataract, Dry Eye Syndrome, Macular Degeneration, Diabetic Macular Edema, Refractive Issues), Setting (Hospitals, Clinics, Homecare Settings, ASCs, Others), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific ophthalmic drug delivery system market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Asia Pacific ophthalmic drug delivery system market in every aspect of the classification from perspectives of Product, Dosage Form, Disease, Setting, and Country. Based on Product, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Pre-filled Syringes • Multidose Eyedroppers • Squeeze Dispensers • Mist Sprayers • Contact Lenses • Ocular Inserts • Intraocular Implants • Punctal Plugs • Other Products Based on Dosage Form, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Solutions • Gels • Ointments • Suspensions • Emulsions • Liposomes & Nanoparticles By Disease, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Glaucoma • Diabetic Retinopathy • Cataract • Dry Eye Syndrome • Macular Degeneration • Diabetic Macular Edema • Refractive Issues • Other Diseases By Setting, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Hospitals • Clinics • Homecare Settings • Ambulatory Surgical Centers (ASCs) • Other Settings Geographically, the following national/local markets are fully investigated: • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines) For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of national markets by Product, Dosage Form, and Setting over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Selected Key Players: Aero Pump GmbH Allergan plc. AptarGroup, Inc. Becton, Dickinson and Company Biocorp Clearside Biomedical, Inc. EyePoint Pharmaceuticals, Inc. Gaplast GmbH Gerresheimer AG Jotteq Inc. Kedalion Therapeutics, Inc. Mati Therapeutics, Inc. Nemera Nipro Corporation Ocular Therapeutix, Inc. Ocumedic, Inc. Owen Mumford Re-Vana Therapeutics Silgan Holdings Inc. Terumo Corporation Valeant Pharmaceuticals International Inc. (Bausch Health Company) West Pharmaceutical Services, Inc. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table of Contents:
1 Introduction	7
1.1 Industry Definition and Research Scope	7
1.1.1 Industry Definition	7
1.1.2 Research Scope	8
1.2 Research Methodology	11
1.2.1 Overview of Market Research Methodology	11
1.2.2 Market Assumption	12
1.2.3 Secondary Data	12
1.2.4 Primary Data	12
1.2.5 Data Filtration and Model Design	13
1.2.6 Market Size/Share Estimation	14
1.2.7 Research Limitations	15
1.3 Executive Summary	16
2 Market Overview and Dynamics	19
2.1 Market Size and Forecast	19
2.1.1 Impact of COVID-19 on World Economy	21
2.1.2 Impact of COVID-19 on the Market	23
2.2 Major Growth Drivers	25
2.3 Market Restraints and Challenges	29
2.4 Emerging Opportunities and Market Trends	32
2.5 Porter’s Fiver Forces Analysis	36
3 Segmentation of Asia Pacific Market by Product	40
3.1 Market Overview by Product	40
3.2 Pre-filled Syringes	42
3.3 Multidose Eyedroppers	43
3.4 Squeeze Dispensers	44
3.5 Mist Sprayers	45
3.6 Contact Lenses	46
3.7 Ocular Inserts	47
3.8 Intraocular Implants	48
3.9 Punctal Plugs	49
3.10 Other Products	50
4 Segmentation of Asia Pacific Market by Dosage Form	51
4.1 Market Overview by Dosage Form	51
4.2 Solutions	53
4.3 Gels	54
4.4 Ointments	55
4.5 Suspensions	56
4.6 Emulsions	57
4.7 Liposomes & Nanoparticles	58
5 Segmentation of Asia Pacific Market by Disease	59
5.1 Market Overview by Disease	59
5.2 Glaucoma	61
5.3 Diabetic Retinopathy	62
5.4 Cataract	63
5.5 Dry Eye Syndrome	64
5.6 Macular Degeneration	65
5.7 Diabetic Macular Edema	66
5.8 Refractive Issues	67
5.9 Other Diseases	68
6 Segmentation of Asia Pacific Market by Setting	69
6.1 Market Overview by Setting	69
6.2 Hospitals	71
6.3 Clinics	72
6.4 Homecare Settings	73
6.5 Ambulatory Surgical Centers (ASCs)	74
6.6 Other Settings	75
7 Asia-Pacific Market 2021-2031 by Country	76
7.1 Overview of Asia-Pacific Market	76
7.2 Japan	79
7.3 China	83
7.4 Australia	86
7.5 India	89
7.6 South Korea	92
7.7 Rest of APAC Region	95
8 Competitive Landscape	97
8.1 Overview of Key Vendors	97
8.2 New Product Launch, Partnership, Investment, and M&A	100
8.3 Company Profiles	101
Aero Pump GmbH	101
Allergan plc.	103
AptarGroup, Inc.	104
Becton, Dickinson and Company	105
Biocorp	106
Clearside Biomedical, Inc.	107
EyePoint Pharmaceuticals, Inc.	108
Gaplast GmbH	109
Gerresheimer AG	110
Jotteq Inc.	111
Kedalion Therapeutics, Inc.	112
Mati Therapeutics, Inc.	113
Nemera	114
Nipro Corporation	115
Ocular Therapeutix, Inc.	116
Ocumedic, Inc.	117
Owen Mumford	118
Re-Vana Therapeutics	119
Silgan Holdings Inc.	120
Terumo Corporation	121
Valeant Pharmaceuticals International Inc. (Bausch Health Company)	122
West Pharmaceutical Services, Inc.	123
RELATED REPORTS	124
List of Tables:

Table 1.  Snapshot of Asia Pacific Ophthalmic Drug Delivery System Market in Balanced Perspective, 2021-2031	17
Table 2. World Economic Outlook, 2021-2031	22
Table 3.  Main Product Trends and Market Opportunities in Asia Pacific Ophthalmic Drug Delivery System Market	32
Table 4. Asia Pacific Ophthalmic Drug Delivery System Market by Product, 2021-2031, $ mn	40
Table 5. Asia Pacific Ophthalmic Drug Delivery System Market by Dosage Form, 2021-2031, $ mn	51
Table 6. Asia Pacific Ophthalmic Drug Delivery System Market by Disease, 2021-2031, $ mn	59
Table 7. Asia Pacific Ophthalmic Drug Delivery System Market by Setting, 2021-2031, $ mn	69
Table 8. APAC Ophthalmic Drug Delivery System Market by Country, 2021-2031, $ mn	77
Table 9. Japan Ophthalmic Drug Delivery System Market by Product, 2021-2031, $ mn	81
Table 10. Japan Ophthalmic Drug Delivery System Market by Dosage Form, 2021-2031, $ mn	81
Table 11. Japan Ophthalmic Drug Delivery System Market by Setting, 2021-2031, $ mn	82
Table 12. China Ophthalmic Drug Delivery System Market by Product, 2021-2031, $ mn	84
Table 13. China Ophthalmic Drug Delivery System Market by Dosage Form, 2021-2031, $ mn	84
Table 14. China Ophthalmic Drug Delivery System Market by Setting, 2021-2031, $ mn	85
Table 15. Australia Ophthalmic Drug Delivery System Market by Product, 2021-2031, $ mn	87
Table 16. Australia Ophthalmic Drug Delivery System Market by Dosage Form, 2021-2031, $ mn	87
Table 17. Australia Ophthalmic Drug Delivery System Market by Setting, 2021-2031, $ mn	88
Table 18. India Ophthalmic Drug Delivery System Market by Product, 2021-2031, $ mn	90
Table 19. India Ophthalmic Drug Delivery System Market by Dosage Form, 2021-2031, $ mn	90
Table 20. India Ophthalmic Drug Delivery System Market by Setting, 2021-2031, $ mn	91
Table 21. South Korea Ophthalmic Drug Delivery System Market by Product, 2021-2031, $ mn	93
Table 22. South Korea Ophthalmic Drug Delivery System Market by Dosage Form, 2021-2031, $ mn	93
Table 23. South Korea Ophthalmic Drug Delivery System Market by Setting, 2021-2031, $ mn	94
Table 24. Ophthalmic Drug Delivery System Market in Rest of APAC by Country/Region, 2021-2031, $ mn	96
Table 25. Aero Pump GmbH: Company Snapshot	101
Table 26. Aero Pump GmbH: Business Segmentation	102
Table 27. Aero Pump GmbH: Product Portfolio	102
List of Figures:

Figure 1. Research Method Flow Chart	11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation	14
Figure 3. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2021-2031	16
Figure 4. Industry Value Chain Analysis	19
Figure 5. Asia Pacific Ophthalmic Drug Delivery System Market, 2021-2031, $ mn	20
Figure 6. Impact of COVID-19 on Business	23
Figure 7. Primary Drivers and Impact Factors of Asia Pacific Ophthalmic Drug Delivery System Market	25
Figure 8. Number of Population Affected by Vision Impairment, All Ages by Sex, 1990–2050F	28
Figure 9. Primary Restraints and Impact Factors of Asia Pacific Ophthalmic Drug Delivery System Market	29
Figure 10. Investment Opportunity Analysis	33
Figure 11. Porter’s Fiver Forces Analysis of Asia Pacific Ophthalmic Drug Delivery System Market	36
Figure 12. Breakdown of Asia Pacific Ophthalmic Drug Delivery System Market by Product, 2021-2031, % of Revenue	41
Figure 13. Asia Pacific Addressable Market Cap in 2022-2031 by Product, Value ($ mn) and Share (%)	41
Figure 14. Asia Pacific Ophthalmic Drug Delivery System Market by Product: Pre-filled Syringes, 2021-2031, $ mn	42
Figure 15. Asia Pacific Ophthalmic Drug Delivery System Market by Product: Multidose Eyedroppers, 2021-2031, $ mn	43
Figure 16. Asia Pacific Ophthalmic Drug Delivery System Market by Product: Squeeze Dispensers, 2021-2031, $ mn	44
Figure 17. Asia Pacific Ophthalmic Drug Delivery System Market by Product: Mist Sprayers, 2021-2031, $ mn	45
Figure 18. Asia Pacific Ophthalmic Drug Delivery System Market by Product: Contact Lenses, 2021-2031, $ mn	46
Figure 19. Asia Pacific Ophthalmic Drug Delivery System Market by Product: Ocular Inserts, 2021-2031, $ mn	47
Figure 20. Asia Pacific Ophthalmic Drug Delivery System Market by Product: Intraocular Implants, 2021-2031, $ mn	48
Figure 21. Asia Pacific Ophthalmic Drug Delivery System Market by Product: Punctal Plugs, 2021-2031, $ mn	49
Figure 22. Asia Pacific Ophthalmic Drug Delivery System Market by Product: Other Products, 2021-2031, $ mn	50
Figure 23. Breakdown of Asia Pacific Ophthalmic Drug Delivery System Market by Dosage Form, 2021-2031, % of Sales Revenue	52
Figure 24. Asia Pacific Addressable Market Cap in 2022-2031 by Dosage Form, Value ($ mn) and Share (%)	52
Figure 25. Asia Pacific Ophthalmic Drug Delivery System Market by Dosage Form: Solutions, 2021-2031, $ mn	53
Figure 26. Asia Pacific Ophthalmic Drug Delivery System Market by Dosage Form: Gels, 2021-2031, $ mn	54
Figure 27. Asia Pacific Ophthalmic Drug Delivery System Market by Dosage Form: Ointments, 2021-2031, $ mn	55
Figure 28. Asia Pacific Ophthalmic Drug Delivery System Market by Dosage Form: Suspensions, 2021-2031, $ mn	56
Figure 29. Asia Pacific Ophthalmic Drug Delivery System Market by Dosage Form: Emulsions, 2021-2031, $ mn	57
Figure 30. Asia Pacific Ophthalmic Drug Delivery System Market by Dosage Form: Liposomes & Nanoparticles, 2021-2031, $ mn	58
Figure 31. Breakdown of Asia Pacific Ophthalmic Drug Delivery System Market by Disease, 2021-2031, % of Sales Revenue	60
Figure 32. Asia Pacific Addressable Market Cap in 2022-2031 by Disease, Value ($ mn) and Share (%)	60
Figure 33. Asia Pacific Ophthalmic Drug Delivery System Market by Disease: Glaucoma, 2021-2031, $ mn	61
Figure 34. Asia Pacific Ophthalmic Drug Delivery System Market by Disease: Diabetic Retinopathy, 2021-2031, $ mn	62
Figure 35. Asia Pacific Ophthalmic Drug Delivery System Market by Disease: Cataract, 2021-2031, $ mn	63
Figure 36. Asia Pacific Ophthalmic Drug Delivery System Market by Disease: Dry Eye Syndrome, 2021-2031, $ mn	64
Figure 37. Asia Pacific Ophthalmic Drug Delivery System Market by Disease: Macular Degeneration, 2021-2031, $ mn	65
Figure 38. Asia Pacific Ophthalmic Drug Delivery System Market by Disease: Diabetic Macular Edema, 2021-2031, $ mn	66
Figure 39. Asia Pacific Ophthalmic Drug Delivery System Market by Disease: Refractive Issues, 2021-2031, $ mn	67
Figure 40. Asia Pacific Ophthalmic Drug Delivery System Market by Disease: Other Diseases, 2021-2031, $ mn	68
Figure 41. Breakdown of Asia Pacific Ophthalmic Drug Delivery System Market by Setting, 2021-2031, % of Revenue	70
Figure 42. Asia Pacific Addressable Market Cap in 2022-2031 by Setting, Value ($ mn) and Share (%)	70
Figure 43. Asia Pacific Ophthalmic Drug Delivery System Market by Setting: Hospitals, 2021-2031, $ mn	71
Figure 44. Asia Pacific Ophthalmic Drug Delivery System Market by Setting: Clinics, 2021-2031, $ mn	72
Figure 45. Asia Pacific Ophthalmic Drug Delivery System Market by Setting: Homecare Settings, 2021-2031, $ mn	73
Figure 46. Asia Pacific Ophthalmic Drug Delivery System Market by Setting: Ambulatory Surgical Centers (ASCs), 2021-2031, $ mn	74
Figure 47. Asia Pacific Ophthalmic Drug Delivery System Market by Setting: Other Settings, 2021-2031, $ mn	75
Figure 48. Breakdown of APAC Ophthalmic Drug Delivery System Market by Country, 2021 and 2031, % of Revenue	77
Figure 49. Contribution to APAC 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%)	78
Figure 50.  Ophthalmic Drug Delivery System Market in Japan, 2021-2031, $ mn	80
Figure 51.  Ophthalmic Drug Delivery System Market in China, 2021-2031, $ mn	83
Figure 52.  Ophthalmic Drug Delivery System Market in Australia, 2021-2031, $ mn	86
Figure 53.  Ophthalmic Drug Delivery System Market in India, 2021-2031, $ mn	89
Figure 54.  Ophthalmic Drug Delivery System Market in South Korea, 2021-2031, $ mn	92
Figure 55.  Ophthalmic Drug Delivery System Market in Rest of APAC, 2021-2031, $ mn	95
Figure 56. Growth Stage of Asia Pacific Ophthalmic Drug Delivery System Industry over the Forecast Period	97
Selected Key Players: 
Aero Pump GmbH
Allergan plc.
AptarGroup, Inc.
Becton, Dickinson and Company
Biocorp
Clearside Biomedical, Inc.
EyePoint Pharmaceuticals, Inc.
Gaplast GmbH
Gerresheimer AG
Jotteq Inc.
Kedalion Therapeutics, Inc.
Mati Therapeutics, Inc.
Nemera
Nipro Corporation
Ocular Therapeutix, Inc.
Ocumedic, Inc.
Owen Mumford
Re-Vana Therapeutics
Silgan Holdings Inc.
Terumo Corporation
Valeant Pharmaceuticals International Inc. (Bausch Health Company)
West Pharmaceutical Services, Inc. 
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)